FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994185611> ?p ?o ?g. }

• W1994185611 endingPage "1459" @default.
• W1994185611 startingPage "1456" @default.
• W1994185611 abstract "Background. Although expression of the HER-2/neu oncogene may be of some prognostic importance in advanced ovarian cancer, its role in early-stage disease has not been established. The current study examined the prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Methods. The authors analyzed the expression of HER-2/neu on frozen tumor specimens from 40 patients with early epithelial ovarian cancer using the indirect immunoperoxidase technique with monoclonal antibodies that detect epitopes on the extracellular domain of the HER-2/neu protein. All patients underwent comprehensive surgical staging. HER-2/neu expression was graded as negative, weak, moderate (1+ to 2+), or strong (3+). Complete clinical data and long-term follow up were available for all patients. Results. The distribution of patients by stage was as follows: Stage IA, 6; IB, 0; IC, 14; IIA, 4; IIB, 6; IIC, 10. The mean patient age was 53 years. Fourteen patients had serous tumors; nine, endometrioid; eight, clear cell; eight, mucinous; and one, undifferentiated. Intratumoral heterogeneity of HER-2/neu expression was observed with most specimens. In eight specimens (20%), some areas of the tumor showed strong (3+) expression, beyond the level that can be seen in normal ovarian epithelium. Twenty-eight specimens (70%) showed moderate (1+ to 2+) staining, whereas four specimens (10%) showed negative or weak staining. At a mean follow-up time among surviving patients of 32 months, 15 patients (37%) have had cancer recurrence. No statistically significant relationship was found between HER-2/neu expression and survival, disease-free survival, stage, or grade. A significant increase was found in 3+ expression of HER-2/neu in clear cell tumors. Conclusion. Consistent HER-2/neu overexpression occurs infrequently in early ovarian cancer, making it unlikely that such overexpression is a general early event in ovarian carcinogenesis. HER-2/neu expression does not appear to be a strong prognostic marker in early epithelial ovarian cancer. Cancer 1994; 73:1456–9." @default.
• W1994185611 created "2016-06-24" @default.
• W1994185611 creator A5012218355 @default.
• W1994185611 creator A5023540371 @default.
• W1994185611 creator A5041216993 @default.
• W1994185611 creator A5048534007 @default.
• W1994185611 creator A5059856518 @default.
• W1994185611 creator A5073951552 @default.
• W1994185611 date "1994-03-01" @default.
• W1994185611 modified "2023-10-14" @default.
• W1994185611 title "Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer" @default.
• W1994185611 cites W1755920412 @default.
• W1994185611 cites W1924784781 @default.
• W1994185611 cites W1973033337 @default.
• W1994185611 cites W1973188134 @default.
• W1994185611 cites W1998668912 @default.
• W1994185611 cites W2001627828 @default.
• W1994185611 cites W2033748688 @default.
• W1994185611 cites W2043471865 @default.
• W1994185611 cites W2077263403 @default.
• W1994185611 cites W2084548343 @default.
• W1994185611 cites W2095156669 @default.
• W1994185611 cites W2136779985 @default.
• W1994185611 cites W2151127067 @default.
• W1994185611 cites W2323254708 @default.
• W1994185611 cites W4255602882 @default.
• W1994185611 cites W4293241248 @default.
• W1994185611 doi "https://doi.org/10.1002/1097-0142(19940301)73:5<1456::aid-cncr2820730522>3.0.co;2-l" @default.
• W1994185611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7906607" @default.
• W1994185611 hasPublicationYear "1994" @default.
• W1994185611 type Work @default.
• W1994185611 sameAs 1994185611 @default.
• W1994185611 citedByCount "63" @default.
• W1994185611 countsByYear W19941856112012 @default.
• W1994185611 countsByYear W19941856112013 @default.
• W1994185611 countsByYear W19941856112014 @default.
• W1994185611 countsByYear W19941856112015 @default.
• W1994185611 countsByYear W19941856112017 @default.
• W1994185611 countsByYear W19941856112019 @default.
• W1994185611 countsByYear W19941856112020 @default.
• W1994185611 countsByYear W19941856112023 @default.
• W1994185611 crossrefType "journal-article" @default.
• W1994185611 hasAuthorship W1994185611A5012218355 @default.
• W1994185611 hasAuthorship W1994185611A5023540371 @default.
• W1994185611 hasAuthorship W1994185611A5041216993 @default.
• W1994185611 hasAuthorship W1994185611A5048534007 @default.
• W1994185611 hasAuthorship W1994185611A5059856518 @default.
• W1994185611 hasAuthorship W1994185611A5073951552 @default.
• W1994185611 hasConcept C121608353 @default.
• W1994185611 hasConcept C126322002 @default.
• W1994185611 hasConcept C128102431 @default.
• W1994185611 hasConcept C142724271 @default.
• W1994185611 hasConcept C143998085 @default.
• W1994185611 hasConcept C146357865 @default.
• W1994185611 hasConcept C150173356 @default.
• W1994185611 hasConcept C151730666 @default.
• W1994185611 hasConcept C159654299 @default.
• W1994185611 hasConcept C203014093 @default.
• W1994185611 hasConcept C204232928 @default.
• W1994185611 hasConcept C2776872082 @default.
• W1994185611 hasConcept C2780427987 @default.
• W1994185611 hasConcept C530470458 @default.
• W1994185611 hasConcept C542903549 @default.
• W1994185611 hasConcept C63363279 @default.
• W1994185611 hasConcept C71924100 @default.
• W1994185611 hasConcept C86803240 @default.
• W1994185611 hasConceptScore W1994185611C121608353 @default.
• W1994185611 hasConceptScore W1994185611C126322002 @default.
• W1994185611 hasConceptScore W1994185611C128102431 @default.
• W1994185611 hasConceptScore W1994185611C142724271 @default.
• W1994185611 hasConceptScore W1994185611C143998085 @default.
• W1994185611 hasConceptScore W1994185611C146357865 @default.
• W1994185611 hasConceptScore W1994185611C150173356 @default.
• W1994185611 hasConceptScore W1994185611C151730666 @default.
• W1994185611 hasConceptScore W1994185611C159654299 @default.
• W1994185611 hasConceptScore W1994185611C203014093 @default.
• W1994185611 hasConceptScore W1994185611C204232928 @default.
• W1994185611 hasConceptScore W1994185611C2776872082 @default.
• W1994185611 hasConceptScore W1994185611C2780427987 @default.
• W1994185611 hasConceptScore W1994185611C530470458 @default.
• W1994185611 hasConceptScore W1994185611C542903549 @default.
• W1994185611 hasConceptScore W1994185611C63363279 @default.
• W1994185611 hasConceptScore W1994185611C71924100 @default.
• W1994185611 hasConceptScore W1994185611C86803240 @default.
• W1994185611 hasIssue "5" @default.
• W1994185611 hasLocation W19941856111 @default.
• W1994185611 hasLocation W19941856112 @default.
• W1994185611 hasOpenAccess W1994185611 @default.
• W1994185611 hasPrimaryLocation W19941856111 @default.
• W1994185611 hasRelatedWork W1976902109 @default.
• W1994185611 hasRelatedWork W2093406717 @default.
• W1994185611 hasRelatedWork W2093855470 @default.
• W1994185611 hasRelatedWork W2146105412 @default.
• W1994185611 hasRelatedWork W2318848311 @default.
• W1994185611 hasRelatedWork W2404221170 @default.
• W1994185611 hasRelatedWork W2425319183 @default.
• W1994185611 hasRelatedWork W2432787173 @default.
• W1994185611 hasRelatedWork W4253422358 @default.

• next